IP Verse

Medicaments For Increasing Endogenous Erythropoietine (Epo)

Patent No. EP2289531 (titled "Medicaments For Increasing Endogenous Erythropoietine (Epo)") was filed by Fibrogen on Dec 6, 2002. The application was issued on Jul 4, 2018.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GLAXOSMITHKLINEFeb 19, 2020GODDARD
AKEBIA THERAPEUTICSApr 3, 2019JONES DAY

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2289531

FIBROGEN
Application Number
EP10181768A
Filing Date
Dec 6, 2002
Status
Revoked
May 16, 2025
Publication Date
Jul 4, 2018
External Links
Slate, Register , Google Patents